IL15 and acute myeloid leukemia: Another phase II clinical trial took place in which same donor-memory like (ML) NK cells were infused along with N-803 (IL-15 superagonist) to patients with relapsed/refractory (rel/ref) AML after intake of reduced intensity regimen before HLA-HCT [8].